Trial Profile
A Phase II Trial of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Hormone Resistant Prostate Cancer (HRPC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Epirubicin (Primary) ; Estramustine (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Mar 2010 Interim results (n=14) presented at ASCO Genitourinary Cancers Symposium 2010.
- 03 Nov 2005 New trial record.